Phylogica will use its Phylomer platform to identify peptides suitable for further evaluation.
Phylogica entered into a collaboration and licensing agreement with Pfizer to discover novel peptide-based vaccines. In the deal, Phylogica will receive an up-front payment of $500,000. In addition, Phylogica is eligible to receive a commercial license payment and is also eligible to receive preclinical, clinical, and other milestone payments of up to $134 million as well as royalties on worldwide sales.
Under the agreement, Phylogica will employ its Phylomer® drug-discovery platform to identify Phylomer peptides suitable for further evaluation. Phylogica is granting Pfizer certain rights including an option to license any resulting Phylomers for further research, development, and commercialization of novel peptide-based vaccines derived from such Phylomers.
“This alliance supports the potential utility of Phylogica’s Phylomer drug-discovery platform for peptide-based drug discovery. With the present announcement, Phylogica has now entered into three alliances with global pharmaceutical companies within the last 12 months,” says Paul Watt, Ph.D., founder and CEO of Phylogica.
Phylomer peptides are derived from biodiverse natural sequences, which have been selected by evolution to form stable structures, which can bind tightly and specifically to disease-associated target proteins both inside and outside cells, according to Phylogica. Suitable targets for blockade by Phylomers include protein interactions that promote multiple diseases such as infectious diseases, cancer, autoimmunity, and heart disease.